These press releases are for business and financial media.
-
-
- Press release archive 2008
- 04 November 2008
- John Patterson to Retire from AstraZeneca AstraZeneca today announced that John Patterson, Executive Director, Development will retire from the company in March 2009.
-
-
-
- Press release archive 2008
- 30 October 2008
- AstraZeneca PLC Third Quarter and Nine Months Results 2008 AstraZeneca has delivered a robust set of results, and on the back of this, is raising financial guidance for the full year. Additionally good progress is being made on reshaping the cost base, including advancing innovation in research and development activities with greater productivity and efficiency.
-
-
-
- Press release archive 2008
- 21 October 2008
- AstraZeneca Announces European SEROQUEL XR Submission for the Treatment of Generalised Anxiety Disorder AstraZeneca today announced its submission of SEROQUEL XR (quetiapine fumarate extended release tablets) to European regulatory authorities seeking approval for both short-term and maintenance treatment of Generalised Anxiety Disorder (GAD). This is the first time approval has been sought in Europe for an atypical antipsychotic medicine for the treatment of GAD.
-
-
-
- Press release archive 2008
- 17 October 2008
- AstraZeneca and POZEN Informed of FDA Internal Review of Gastric Ulcers as a Primary Endpoint in Trials AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today that the U.S. Food and Drug Administration (FDA) has informed POZEN that it is conducting an internal review on the acceptability of endoscopic gastric ulcers as a primary endpoint in clinical studies. The FDA has not indicated when their internal review will be completed, although an FDA internal meeting has been scheduled to review this subject during the first quarter of 2009.
-
-
-
- Press release archive 2008
- 10 October 2008
- FDA Approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.
-
-
-
- Press release archive 2008
- 24 September 2008
- US Court Denies Teva’s Motion For Summary Judgment In Pulmicort Respules Patent Litigation AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva’s Motion for Summary Judgment of no infringement in the PULMICORT RESPULES (budesonide inhalation suspension) patent litigation.
-
-
-
- Press release archive 2008
- 16 September 2008
- AstraZeneca and Targacept Announce Top-Line Results From Phase IIb Study of AZD3480 in Alzheimer’s Disease Results inconclusive, as primary outcome measure not statistically significant for either donepezil or AZD3480; results impacted by improvement in placebo group Improvements shown on secondary outcome measures ADCS-CGIC and MMSE Overall safety and tolerability profile comparable to placebo, with fewer GI-related AEs than donepezil Next steps include further analysis of full dataset and planned discussions with leading medical experts
-
-
-
- Press release archive 2008
- 12 September 2008
- AstraZeneca PLC Appoints New Non-Executive Director AstraZeneca today announced that Rudy Markham is to join the Board of Directors as a Non-Executive Director with immediate effect. Rudy Markham was formerly Chief Financial Officer of Unilever. He is currently a Non-Executive Director of Legal and General Group Plc, Standard Chartered PLC and United Parcel Service, Inc. He is also a member of Board of the Financial Reporting Council.
-
-
-
- Press release archive 2008
- 09 September 2008
- New Data for Investigational Diabetes Drug Saxagliptin Demonstrates Potential for Type 2 Diabetes Treatment New data presented for the first time at EASD 2008 Saxagliptin with metformin as initial combination therapy lowered A1C Improvements demonstrated across key measures of glucose control studied in treatment-naïve people with type 2 diabetes
-
-
-
- Press release archive 2008
- 08 September 2008
- Saxagliptin Improved Key Measures of Glucose Control When Added to a Sulphonylurea or Thiazolidinedione in People with Inadequately Controlled Type 2 Diabetes Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrate that saxagliptin produced reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glucose (FPG) and postprandial glucose (PPG)] when added to a sulphonylurea (SU) or a thiazolidinedione (TZD) in people with inadequately controlled type 2 diabetes, compared with placebo added to either an increased dose of SU or a
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 09:18 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
